Plaintiff
1 case as plaintiff.
New York Hotel Trades Council & Hotel Association of New York City, Inc., Health Center, Inc. (commonly "HCI" or the HTC Health Center, part of the Hotel Trades Council Employee Benefit Funds) is a New York not-for-profit corporation headquartered at 305 West 44th Street, New York, NY. It was established in 1949 under federal law as an ERISA-regulated health benefit plan and is organized as a 501(c)(9) voluntary employees' beneficiary association, jointly trusteed by union- and employer-designated trustees. It is not publicly traded. Its most recent IRS Form 990 (FY2024) reports roughly $294 million in revenue, about $283 million in expenses, and approximately 1,030 employees.
Operations. HCI owns and operates Article 28–licensed diagnostic and treatment centers — in Midtown Manhattan, Harlem, Brooklyn, and Queens — with on-site pharmacies and dental centers. It directly employs physicians, dentists, psychiatrists, nurses, and pharmacy staff and provides primary and specialty medical care, dental and oral surgery, radiology, vision, mental-health and addiction services, and prescription dispensing, at little or no cost to eligible New York City hotel and motel union members, their dependents, and retirees. Hospitalization and out-of-area care are delivered through contracted carriers (Anthem BlueCross BlueShield) and referral agreements; a cost-reimbursement contract with CMS covers Medicare-eligible retirees. It is an operating healthcare provider and benefit plan, not a patent-assertion entity.
Litigation posture. The tracked database shows exactly one case: as plaintiff, zero as defendant. This is a purchaser-side antitrust action, not a patent-infringement suit, so it does not reflect a patent-litigation or NPE posture at all.
Notable case. New York Hotel Trades Council & Hotel Association of New York City, Inc. Health Center Inc. v. Celgene Corporation (No. 1:24-cv-02230, S.D.N.Y., filed March 25, 2024) alleged monopolization under 15 U.S.C. §§ 1–2 and state law, claiming Celgene/Bristol Myers Squibb fraudulently procured pomalidomide (Pomalyst) patents, asserted them in sham litigation, and used reverse-payment settlements to delay generics. It was consolidated into the lead case Louisiana Health Service & Indemnity Co. v. Celgene Corp., 1:23-cv-07871-ER (Judge Edgardo Ramos). The court entered judgment for the defendants on April 10, 2026.
Antitrust action in which the '428 patent is cited as part of the challenged Celgene patent portfolio; plaintiff sued Celgene in S.D.N.Y. Status is generally pending/consolidated.